» Articles » PMID: 26554398

Impact of Gender and Menopausal Status on Metabolic Parameters in Chronic Hepatitis C Infection

Overview
Journal J Viral Hepat
Specialty Gastroenterology
Date 2015 Nov 12
PMID 26554398
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C infection (HCV) and menopause are associated with insulin resistance (IR), and IR accelerates HCV-induced liver disease. The relationship between menopause and IR has not been studied in this population. This study aimed to assess the impact of menopause on IR and metabolic syndrome in HCV. One hundred and three (69 men, 16 premenopausal, 18 postmenopausal women) noncirrhotic, nondiabetic HCV-infected adults underwent IR measurement via steady-state plasma glucose during a 240-min insulin suppression test. Metabolic syndrome was defined by at least three of five standard laboratory/clinical criteria. The patient characteristics were as follows: mean age 48 years, waist circumference 94.4 ± 12.4 cm and 37.9% Caucasian. SSPG was higher in postmenopausal than premenopausal women or men (mean difference 18, 95% CI -41 to 76 and 35, 95% CI -3 to 72 mg/dL; respectively). After adjusting for waist circumference, female gender, nonwhite race and triglycerides were positively associated and high-density lipoprotein negatively associated with steady-state plasma glucose. Compared to men, both pre- (Coef 48, 95% CI 12-84) and postmenopausal women (Coef 49, 95% CI 17-82) had higher steady-state plasma glucose. Compared to premenopausal women, men (OR 2.0, 95% CI 0.38-10.2) and postmenopausal women (OR 2.9, 95% CI 0.46-18.8) had higher odds of metabolic syndrome, but this was statistically nonsignificant. Both liver inflammation (OR 7.9) and nonwhite race (OR 6.9) were associated with metabolic syndrome. We conclude that women are at inc-reased risk for IR in HCV. There may also be an increased risk of metabolic syndrome postmenopause. Along with lifestyle modification and weight loss, women with metabolic abnormalities represent an especially at-risk group warranting HCV treatment to prevent adverse metabolic outcomes.

Citing Articles

Disentangling the impact of alcohol use and hepatitis C on insulin action in Latino individuals.

Kim R, Kramer-Feldman J, Bacchetti P, Grimes B, Burchard E, Eng C Alcohol Clin Exp Res. 2021; 46(1):87-99.

PMID: 34773280 PMC: 8799492. DOI: 10.1111/acer.14743.

References
1.
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

2.
Codes L, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Parana R . Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy. Gut. 2006; 56(3):390-5. PMC: 1856786. DOI: 10.1136/gut.2006.101931. View

3.
. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015; 33(2):97-111. PMC: 4398006. DOI: 10.2337/diaclin.33.2.97. View

4.
Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R . Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008; 103(5):1136-44. DOI: 10.1111/j.1572-0241.2008.01813.x. View

5.
Ferrara C, Goldberg A, Nicklas B, Sorkin J, Ryan A . Sex differences in insulin action and body fat distribution in overweight and obese middle-aged and older men and women. Appl Physiol Nutr Metab. 2008; 33(4):784-90. PMC: 2920284. DOI: 10.1139/H08-062. View